









Markets
/
Stocks
/
nasdaq-govx
/

GeoVax Labs Inc

GOVX

2.670USD

+0.090+3.49%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.17MMarket Cap

LossP/E TTM



GeoVax Labs Inc

2.670

+0.090+3.49%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of GeoVax Labs Inc

Currency: USD Updated: 2026-02-06

Key Insights

GeoVax Labs Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 127 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 232.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

GeoVax Labs Inc's Score

Industry at a Glance

Industry Ranking

127 / 392

Overall Ranking

265 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

GeoVax Labs Inc Highlights

StrengthsRisks

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 4750.69% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.95M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.95M.

Overvalued

The company’s latest PE is -0.08, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 139.37K shares, increasing 41.89% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 9.77K shares of this stock.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

232.500

Target Price

+8911.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of GeoVax Labs Inc is 7.86, ranking 74 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 8.66%.

Score

Industry at a Glance

Previous score

7.30

Change

0.56



Financials

7.55

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.99

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.23

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

GeoVax Labs Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of GeoVax Labs Inc is 6.85, ranking 212 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.08, which is -93.80% below the recent high of -0.01 and -3243.86% above the recent low of -2.81.

Score

Industry at a Glance

Previous score

6.85

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 127/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of GeoVax Labs Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.50, with a high of 14.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

232.500

Target Price

+8911.63%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

GeoVax Labs Inc

GOVX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of GeoVax Labs Inc is 6.15, ranking 277 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.88 and the support level at 1.99, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.13

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.315

Neutral

RSI(14)

32.476

Neutral

STOCH(KDJ)(9,3,3)

21.173

Neutral

ATR(14)

0.301

Low Volatility

CCI(14)

-130.353

Sell

Williams %R

82.418

Oversold

TRIX(12,20)

-2.756

Sell

StochRSI(14)

90.053

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.700

Sell

MA10

2.776

Sell

MA20

2.972

Sell

MA50

5.479

Sell

MA100

7.958

Sell

MA200

4.404

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of GeoVax Labs Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 6.61%, representing a quarter-over-quarter increase of 187.82%. The largest institutional shareholder is The Vanguard, holding a total of 9.77K shares, representing 0.56% of shares outstanding, with 32.23% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

L1 Global Manager Pty Limited

1.48M

Armistice Capital LLC

533.90K

The Vanguard Group, Inc.

Star Investors

244.16K

+112.03%

Geode Capital Management, L.L.C.

207.07K

+93.61%

Hudson Bay Capital Management LP

100.00K

Intracoastal Capital, L.L.C.

64.49K

Sabby Management, LLC

661.38K

UBS Switzerland AG

53.77K

-49.64%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of GeoVax Labs Inc is 1.47, ranking 312 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 3.75. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.